INTRODUCTION: In the Malawi ART programme, 92% of 250,000 patients are using the standard first-line regime of stavudine-lamivudine-nevaripine. National ART reports indicate <4% experience ART side effects, much less than expected from literature. METHODS: We interviewed adult patients on standard first-line ART for at least one year, after routine visits to an urban clinic in Blantyre, Malawi. We determined the prevalence of symptoms that are common side-effects, described discrepancies between symptoms that patients reported to us and those that had been recorded by attending staff as side-effects in the point-of-care electronic monitoring system, and studied factors associated with such discrepancies. RESULTS: Of 170 participants, 75 (44%) reported at least one symptom, most common were symptoms suggesting peripheral neuropathy (n=57) and lipodystrophy (n=16). Forty-six (66%) symptomatic patients said they reported symptoms to attending ART staff. Side-effects were recorded in the clinic database for just 4 patients. Toxicity recording was too low for meaningful analysis of factors associated with discrepancies between reporting and recording of side-effects. The prevalence of symptoms indicating characteristic side-effects of the standard first-line regimen was 39% based on interviews, and 2% in the electronic monitoring system. CONCLUSION: There was gross under-recording of side-effects in this setting, mainly due to not recording by ART staff. Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes. Local and national ART reports do not reflect the true toxicity of the standard first line regimen.
INTRODUCTION: In the Malawi ART programme, 92% of 250,000 patients are using the standard first-line regime of stavudine-lamivudine-nevaripine. National ART reports indicate <4% experience ART side effects, much less than expected from literature. METHODS: We interviewed adult patients on standard first-line ART for at least one year, after routine visits to an urban clinic in Blantyre, Malawi. We determined the prevalence of symptoms that are common side-effects, described discrepancies between symptoms that patients reported to us and those that had been recorded by attending staff as side-effects in the point-of-care electronic monitoring system, and studied factors associated with such discrepancies. RESULTS: Of 170 participants, 75 (44%) reported at least one symptom, most common were symptoms suggesting peripheral neuropathy (n=57) and lipodystrophy (n=16). Forty-six (66%) symptomatic patients said they reported symptoms to attending ART staff. Side-effects were recorded in the clinic database for just 4 patients. Toxicity recording was too low for meaningful analysis of factors associated with discrepancies between reporting and recording of side-effects. The prevalence of symptoms indicating characteristic side-effects of the standard first-line regimen was 39% based on interviews, and 2% in the electronic monitoring system. CONCLUSION: There was gross under-recording of side-effects in this setting, mainly due to not recording by ART staff. Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes. Local and national ART reports do not reflect the true toxicity of the standard first line regimen.
Authors: Fatu Forna; Cheryl A Liechty; Peter Solberg; Fred Asiimwe; Willy Were; Jonathan Mermin; Prosper Behumbiize; Tony Tong; John T Brooks; Paul J Weidle Journal: J Acquir Immune Defic Syndr Date: 2007-04-01 Impact factor: 3.731
Authors: Gerald P Douglas; Oliver J Gadabu; Sabine Joukes; Soyapi Mumba; Michael V McKay; Anne Ben-Smith; Andreas Jahn; Erik J Schouten; Zach Landis Lewis; Joep J van Oosterhout; Theresa J Allain; Rony Zachariah; Selma D Berger; Anthony D Harries; Frank Chimbwandira Journal: PLoS Med Date: 2010-08-10 Impact factor: 11.069
Authors: Jerry O Stern; Patrick A Robinson; James Love; Stephan Lanes; Michael S Imperiale; Douglas L Mayers Journal: J Acquir Immune Defic Syndr Date: 2003-09 Impact factor: 3.731
Authors: Johan van Griensven; Ludwig De Naeyer; Thomas Mushi; Sowaf Ubarijoro; Diane Gashumba; Claire Gazille; Rony Zachariah Journal: Trans R Soc Trop Med Hyg Date: 2007-04-30 Impact factor: 2.184
Authors: Monique M R de Maat; Rob ter Heine; Jan W Mulder; Pieter L Meenhorst; Albert T A Mairuhu; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen Journal: Eur J Clin Pharmacol Date: 2003-08-12 Impact factor: 2.953
Authors: Andrew Boulle; Catherine Orrel; Richard Kaplan; Gilles Van Cutsem; Matthew McNally; Katherine Hilderbrand; London Myer; Matthias Egger; David Coetzee; Gary Maartens; Robin Wood Journal: Antivir Ther Date: 2007
Authors: A Kwekwesa; C Kandionamaso; N Winata; E Mwinjiwa; M Joshua; D Garone; R Bedell; J J van Oosterhout Journal: Malawi Med J Date: 2015-09 Impact factor: 0.875
Authors: Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz Journal: Am J Trop Med Hyg Date: 2017-06 Impact factor: 2.345
Authors: Brenda Asiimwe-Kateera; Nienke Veldhuijzen; Jean Paul Balinda; John Rusine; Sally Eagle; Joseph Vyankandondera; Julie Mugabekazi; Pascale Ondoa; Kimberly Boer; Anita Asiimwe; Joep Lange; Peter Reiss; Janneke van de Wijgert Journal: AIDS Res Treat Date: 2015-07-16
Authors: Victor Singano; Alemayehu Amberbir; Daniela Garone; Christopher Kandionamaso; Jack Msonko; Monique van Lettow; Kondwani Kalima; Yamikani Mataka; Gift Kawalazira; Gabriel Mateyu; Aunex Kwekwesa; Alfred Matengeni; Joep J van Oosterhout Journal: PLoS One Date: 2017-11-20 Impact factor: 3.240